Home / Weight loss
No referral, no wait list
Our prescribing pharmacist can assess your eligibility and prescribe Ozempic, Wegovy, or Mounjaro on the spot. Consultation covered by Alberta Health Care, follow-ups every step of the way.
All three are weekly injections. They differ in active ingredient, approved use, maximum dose, and clinical evidence. Our pharmacist helps you choose.
semaglutide 0.5 to 2 mg, weekly
Health Canada approved for type 2 diabetes, widely prescribed off-label for weight loss. Starts at 0.25 mg, titrates over 4 to 8 months. Average ~15% body weight reduction over 68 weeks (STEP trials).
Best for: type 2 diabetes
semaglutide 2.4 mg, weekly
Same active ingredient as Ozempic, but Health Canada approved specifically for chronic weight management in adults with obesity or overweight plus a comorbidity. Higher maintenance dose, dedicated obesity indication, often easier insurance coverage.
Best for: chronic weight management
tirzepatide 2.5 to 15 mg, weekly
Dual agonist activating both GLP-1 and GIP receptors. Approved for type 2 diabetes (off-label for weight). ~22% average body weight reduction at highest dose (SURMOUNT trials). Often reported as stronger appetite suppression.
Best for: stronger appetite control
Your first three months
Starting doses, 0.25 mg semaglutide or 2.5 mg tirzepatide. Expect 1 to 3 kg of weight loss and a tolerability check-in. We focus on settling into the medication before escalating.
Dose increased every 4 weeks as tolerated. Pharmacist follow-up at week 8. Most patients lose 5 to 8% of body weight by week 12 and report significantly reduced hunger and fewer cravings.
Full review with the pharmacist. We assess response (≥5% weight reduction is the clinical responder threshold), handle drug-plan paperwork, and plan the next phase. Expected: 5 to 10% reduction on semaglutide, up to 13% on tirzepatide.
Eligibility
We follow Alberta College of Pharmacy and Health Canada criteria. Walk in for a no-cost eligibility check.
Clinical criteria
Exclusions: personal or family history of medullary thyroid carcinoma or MEN2, active pancreatitis, severe GI conditions, pregnancy or planning pregnancy.
Side effects
First 1 to 4 weeks, many patients experience some nausea, reduced appetite, or mild fatigue as the body adjusts. Manage by eating smaller portions, avoiding high-fat meals, and staying well hydrated. We monitor injection-site reactions, constipation, and adjust as needed.
Cost & coverage
Pharmacist consultation, billed to Alberta Health Care. Drug coverage varies: most private plans (Sun Life, Manulife, Great-West, Canada Life) cover with prior authorization. Provincial plans generally don't cover for obesity without diabetes. Out of pocket: $250 to $400 / month at standard doses. Manufacturer assistance programs available.
Common questions
Yes. Under Alberta's pharmacist prescribing regulations, a pharmacist with additional prescribing authorization (APA) can independently assess eligibility and prescribe GLP-1 medications. We do not need a doctor's referral.
The pharmacist consultation is covered. The medications themselves are generally not covered by provincial drug benefit plans for obesity unless you also have a concurrent type 2 diabetes diagnosis. Most private employer plans do cover them with prior authorization.
Both use semaglutide. Wegovy reaches a higher maintenance dose (2.4 mg vs 2 mg) and carries a dedicated obesity approval, which often simplifies coverage. Ozempic has a longer real-world track record but is technically off-label for weight management.
Most patients begin noticing reduced appetite within the first 1 to 2 weeks. Meaningful weight loss typically begins within 4 to 8 weeks, with the greatest effects accumulating over 6 to 12 months.
No referral required
Our pharmacist runs the consultation, prescribes if eligible, and helps with insurance paperwork the same visit.